Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance) Abou-Alfa, Ghassan K. , Niedzwieski, Donna , Knox, Jennifer J. ... - ASCO GI - J. Clin. Oncol. - 2016 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80802
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - - JAMA Oncol - 2019 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-80802
Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8) Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80802
Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver Alberts, S. R. , Donohue, J. H. , Mahoney, M. R. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N014A
NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary Endpoint - Preliminary Analysis - GI - NCCTG-N044J
Adjuvant mFOLFOX6 +/- Cetuxiumab in KRAS Wild Type Patients With Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147. Alberts, S. R. , Sargent, D. J. , Smyrk, T. C. , Shields, A. F. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N0147
Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. Alberts, S. R. , Thibodeau, S. N. , Sargent, D. J. , Mahoney, M. R. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0147
Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver. Alberts, S. , Mahoney, M. R. , Donohue, J. H. , Roh, M. S. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N9945
Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849 Alberts, S. , Soori, G. , Shi, Q. , Wigle, D. , Sticca, R. , Miller, R. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Preliminary Analysis - GI - N0849
Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Fitch, Tom R. , Kim, George P. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - N044J
Gemcitabine and Doxetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Reid, Joel M. , Morlan, Bruce W. , Farr, Gist H. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - N0041
Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66 Alberts, Steven R. , Roh, Mark S. , Mahoney, Michelle R. ... - - J Clin Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - GI - N9945
Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer Alberts, Steven R. , Sargent, Daniel J. , Nair, Suresh ... - - JAMA - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - N0147
Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. Alberts, Steven R , Sande, Jonathan R , Foster, Nathan R ... - - J Gastrointest Cancer - 2007 Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-N9943
Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial. Alberts, Steven R , Suman, Vera J , Pitot, Henry C ... - - J Gastrointest Cancer - 2007 Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-964251
Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods An, Ming-Wen , Han, Yu , Meyers, Jeffrey P. , Bogaerts, Jan ... - - J. Clin. Oncol - 2015 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N9741
Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) -- Findings from the ACCENT dataset. Andre, T. , Shi, Q. , Yothers, G. , Bot, B. , Haller, D. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Ashley, Amanda C , Sargent, Daniel J , Alberts, Steven R ... - - Cancer - 2007 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - NCCTG-9741
Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators Bardia, A. , Loprinzi, C. , Grothey, A. , Nelson, G. , Alberts, S. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0148
Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators Bardia, Aditya , Loprinzi, Charles , Grothey, Axel , Nelson, Garth ... - - Semin Oncol - 2010 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0148
Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - ASCO - J Clin Oncol - 2019 Abstract - Primary Endpoint - Primary Analysis - GI - A021202
Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581 Bertagnolli, M. M. , Niedzwiecki, D. , Hall, M. , Jewell, S. D. ... - ASCO - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - GI - C9581
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803 Bertagnolli, Monica M. , Niedzwiecki, Donna , Compton, Carolyn C. ... - - J Clin Oncol - 2009 Manuscript - Secondary Endpoint - Primary Analysis - GI - C89803 , C150705
Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803 Bertagnolli, Monica M. , Redston, Mark , Compton, Carolyn C. ... - - J Clin Oncol - 2011 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - C89803 , C9581 , C150705
p27Kip1 in Stage III Colon Cancer: Implications for Outcome Following Adjuvant Chemotherapy in CALGB 89803 Bertagnolli, Monica M. , Warren, Robert S. , Niedzwiecki, Donna ... - - Clin Cancer Res - 2009 Manuscript - Secondary Endpoint - Primary Analysis - GI - C89803 , C150705
Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials Blanke, C. D. , Bot, B. M. , Thomas, D. M. , Bleyer, A. , Kohne, C. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-N9741
Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials Blanke, Charles D. , Bot, Brian M. , Thomas, David M. ... - - J. Clin. Oncol - 2011 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N9741
Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer. Bleiberg, H. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-79-41-51 , NCCTG-83-41-51
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52 Bolton, J. S. , O'Connell, M. J. , Mahoney, M. R. , Farr, G. H. Jr ... - - Clin Colorectal Cancer - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-924652
Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Bonjer, H Jacob , Hop, Wim C J , Nelson, Heidi , Sargent, Daniel J ... - - Arch Surg - 2007 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-1515
Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance) Brown, Justin C , Zhang, Sui , Niedzwiecki, Donna , Saltz, Leonard B ... - - JNCI Cancer Spectr - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-89803
What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings Campbell, M. E. , Mandrekar, S. J. , Hillman, S. L. , Goldberg, R. M. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-N0026 , NCCTG-N9741
Waterfall plots provide detailed information on magnitude of response to conventional chemotherapy in advanced colorectal cancer (ACRC) - lessons learned from N9741. Campbell, M. , Grothey, A. , Sargent, D. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9741
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant (NEO) CRT followed by Local Excision (LE) in uT2 Rectal Cancer (RC) Chan, E. , Shi, Q. , Garcia-Aguilar, J. , Wolff, B. G. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z6041
Association of Family History with Cancer Recurrence and Survival Among Patients with Stage III Colon Cancer Chan, Jennifer A. , Meyerhardt, Jeffrey A. , Niedzwiecki, Donna ... - - JAMA - 2008 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - C89803
Innovative estimation of survival using log-normal survival modelling on ACCENT database Chapman, J W , O'Callaghan, C J , Hu, N , Ding, K , Yothers, G A ... - - Br. J. Cancer - 2013 Manuscript - No-Endpoint Endpoint - Primary Analysis - GI - N0441
Comparison of innovative estimation of efficacy to standard using the ACCENT database. Chapman, J. W. , O'Callaghan, C. , Hu, N. , Ding, K. , Yothers, G. A. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
Bayesian Variable Selection with Joint Modeling of Categorical and Survival Outcomes: An Application to Individualizing Chemotherapy Treatment in Advanced Colorectal Cancer Chen, Wei , Ghosh, Debashis , Raghunathan, Trivellore E. ... - - Biometrics - 2009 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-9741
Predictive and prognostic value of gender in early stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. Cheung, W. Y. , Shi, Q. , O'Connell, M. , Cassidy, J. , Blanke, C. D. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database Cheung, Winson Y. , Shi, Qian , O’Connell, Michael , Cassidy, James ... - - Clin Colorectal Cancer - 2013 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0441 , NCCTG-N0441
Incidence of late recurrence in hormone receptor-positive or negative HER2-positive breast cancer receiving adjuvant trastuzumab: The combined analysis of the NCCTG (Alliance) N9831 and NSABP (NRG) B31 Trials Chumsri, Saranya , Li, Zhou , Serie, Daniel J. ... - SABCS - Cancer Res - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N9831 , NSABP B-31
Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials Chumsri, Saranya , Serie, Daniel , Mashadi-Hossein, Afshin ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9831
Sentinel Lymph Node Biopsy Accurately Stages the Regional Lymph Nodes for T1-T2 Oral Squamous Cell Carcinomas: Results of a Prospective Multi-Institutional Trial Civantos, Francisco J. , Zitsch, Robert P. , Schuller, David E. ... - - J Clin Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z0360
Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001 Corless, C. L. , Ballman, K. V. , Antonescu, C. , Blanke, C. D. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z9001
Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial Corless, Christopher L. , Ballman, Karla V. , Antonescu, Cristina R. ... - - J. Clin. Oncol - 2014 Manuscript - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z9001
Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance) Cushman, Stephanie M. , Jiang, Chen , Hatch, Ace J. , Shterev, Ivo ... - - Clin. Cancer Res. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-80203
Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC) Das, R K , Furchtgott, L , Ou, F-S , Swanson, D , Hayete, B , Harms, B ... - ESMO - Ann Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405
Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identifies heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC) Das, Rahul K , Ou, Fang-Shu , Washburn, Cecilia , Nixon, Andrew B. ... - ESMO GI - Annals of Oncology - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405
Association between 3 year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (REC) in patients receiving cytotoxic adjuvant therapy for colon cancer: Updated findings from the 20,800 patient (Pt) ACCENT dataset De Gramont, A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - N0441
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor (GIST): ACOSOG Z9000 (Alliance) intergroup phase 2 trial DeMatteo, Ronald P. , Ballman, Karla V. , Antonescu, Cristina R. ... - - Ann. Surg. - 2013 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - ACOSOG-Z9000
Placebo-Controlled Randomized Trial of Adjuvant Imatinib Mesylate Following the Resection of Localized, Primary Gastrointestinal Stromal Tumor (GIST) DeMatteo, Ronald P. , Ballman, Karla V. , Antonescu, Cristina R. ... - - Lancet - 2009 Manuscript - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9001
Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000 Dematteo, R. P. , Owzar, K. , Antonescu, C. R. , Maki, R. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9000
Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001 Dematteo, R. , Owzar, K. , Maki, R. , Pisters, P. , Blackstein, M. ... - ASCO - ASCO Annual Meeting - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9001
A cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE nested in a multicenter trial of multimodal therapy for rectal cancer (Alliance N1048 PROSPECT) Dueck, Amylou C. , Mitchell, S.A. , Rogak, Lauren I. , Ginos, Brenda ... - ISOQOL - Qual Life Res - 2015 Abstract - Secondary Endpoint - Primary Analysis - GI - N1048
Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144 Dy, Grace K. , Hobday, Timothy J. , Nelson, Garth ... - - Clin Colorectal Cancer - 2009 Manuscript - Primary Endpoint - Primary Analysis - GI - N0144
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. Dy, Grace K , Krook, James E , Green, Erin M , Sargent, Daniel J ... - - J. Clin. Oncol. - 2007 Manuscript - Secondary Endpoint - Primary Analysis - GI - N9741
CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer Enzinger, P. C. , Burtness, B. , Hollis, D. R. , Niedzwiecki, D. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80403
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers Enzinger, Peter C. , Burtness, Barbara Ann , Niedzwiecki, Donna ... - - J. Clin. Oncol - 2016 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-80403 , ECOG-1206
Nut Consumption and Survival in Stage III Colon Cancer Patients: Results from CALGB 89803 (Alliance) Fadelu, Temidayo , Sui Zhang , Donna Niedzwiecki , Xing Ye ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-89803
Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance) Fadelu, Temidayo , Zhang, Sui , Niedzwiecki, Donna , Ye, Xing ... - - J. Clin. Oncol - 2018 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
Lymphatic Drainage Patterns in Oral Squamous Cell Carcinoma: Findings of the ACOSOG Z0360 (Alliance) Study Farmer, Roger W. , McCall, Linda , Civantos, Francisco J. ... - - Otolaryngol Head Neck Surg - 2015 Manuscript - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z0360
Causal modeling of CALGB 80405 (Alliance) identifies network drivers of metastatic colorectal cancer (CRC) Federico Innocenti , Heinz-Josef Lenz , Jeffrey Meyerhardt ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405
Five year results from the COST trial testing laparoscopic versus open colectomy for colon cancer Fleshman, J. , Sargent, D. , Green, E. , Anvari, M. , Stryker, S. ... - - EJC Supplement - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - INT-0146
Disease Free Survival and Local Recurrence for Laparoscopic Resection Compared to Open Resection of Stage II-III Rectal Cancer: Follow up Results of the ACOSOG Z6051 Randomized Controlled Trial Fleshman, J , Branda, ME , Sargent, DJ , Boller, AM , George, VV ... - - Ann. Surg. - 2019 Manuscript - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z6051
Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes Fleshman, James , Branda, Megan , Sargent, Daniel J. ... - - JAMA - 2015 Manuscript - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z6051
Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Fleshman, James , Sargent, Daniel J , Green, Erin , Anvari, Mehran ... - - Ann. Surg. - 2007 Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-1515
Body mass index (BMI) and DNA mismatch repair status in colon cancers from patients treated in adjuvant therapy trials. Foster, N. R. , Sinicrope, F. , Yothers, G. , Allegra, C. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - N994C
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of NCCTGs phase III trials N9741 and N9841. Franko, J. , Shi, Q. , Goldman, C. D. , Pockaj, B. A. , Nelson, G. D. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N9841 , N9741
Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841 Franko, Jan , Shi, Qian , Goldman, Charles D. , Pockaj, Barbara A. ... - - J Clin Oncol - 2012 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N9841 , N9741
Model-based prediction of defective DNA mismatch repair using clinicopathological variables in stage II and III colon cancers. French, A. , Sinicrope, F. , Foster, N. , Thibodeau, S. , Sargent, D. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N994C
Prognostic Significance of Defective Mismatch Repair and BRAF-V600E in Patients with Colon Cancer French, Amy J. , Sargent, Daniel J. , Burgart, Lawrence J. ... - - Clin Cancer Res - 2008 Manuscript - Secondary Endpoint - Primary Analysis - GI - NCCTG-98-46-54
Dietary and lifestyle determinants of colon cancer recurrence and survival Fuchs, C. S. , Meyerhardt, J. A. , Ng, K. , Niedzwiecki, D. ... - NCI TSM - - 2008 Abstract - Secondary Endpoint - Long-Term-Followup Analysis - GI - C89803
KRAS mutation, cancer recurrence and patient survival in stage III colon cancer: Findings from CALGB 89803 Fuchs, C. S. , Ogino, S. , Meyerhardt, J. A. , Irahara, N. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - GI - C89803
Postoperative adjuvant chemoradiation for gastric or gastroesophageal (GE) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): Results from Intergroup trial CALGB 80101 Fuchs, C. S. , Tepper, J. E. , Niedzwiecki, D. , Hollis, D. R. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80101
Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741 Fuchs, Charles S. , Goldberg, Richard M. , Sargent, Daniel J. ... - - Clin Cancer Res - 2008 Manuscript - Secondary Endpoint - Primary Analysis - GI - N9741
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance) Fuchs, Charles S. , Niedzwiecki, Donna , Mamon, Harvey J. ... - - J. Clin. Oncol - 2017 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-80101
Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance) Fuchs, M. A. , Yuan, C. , Sato, K. , Niedzwiecki, D. , Ye, X. ... - - Ann. Oncol - 2017 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance) Fuchs, Michael A. , Sato, Kaori , Niedzwiecki, Donna , Ye, Xing ... - - PLoS ONE - 2014 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary tumor side. Furchtgott, Leon , Swanson, David , Hayete, Boris , Khalil, Iya ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405
Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) and local excision (LE) for uT2uN0 rectal cancer (RC): results of the ACOSOG Z6041 trial Garcia-Aguilar, J. , Shi, Q. , Thomas, C. R. J. , Chan, E. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z6041
Organ preservation for clinical t2n0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision: results of a multicenter phase 2 study Garcia-Aguilar, Julio , Renfro, Lindsay A. , Chow, Oliver S. ... - - Lancet Oncol. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z6041
A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial Garcia-Aguilar, Julio , Shi, Qian , Thomas, Charles R. , Chan, Emily ... - - Ann. Surg. Oncol. - 2012 Manuscript - Primary Endpoint - Preliminary Analysis - GI - ACOSOG-Z6041
RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer Gbenedio, Oghenekevwe M. , Bonnans, Caroline , Grun, Delphine ... - - JCI Insight - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80203 , CALGB-80405
Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!). Gill, S. , Loprinzi, C. , Kennecke, H. , Grothey, A. , Nelson, G. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N0148
Prognostic Web-based Models for Stage II and III Colon Cancer: a Population and Clinical Trials-based Validation of Numeracy and Adjuvant! Online Gill, Sharlene , Loprinzi, Charles , Kennecke, Hagen , Grothey, Axel ... - - Cancer - 2011 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-89-46-51 , NCCTG-914653
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Goel, Ajay , Nagasaka, Takeshi , Arnold, Christian N , Inoue, Toru ... - - Gastroenterology - 2007 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-9865
A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in 9 first line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC). Goldberg, R. M. , Kohne, C. H. , Seymour, M. T. , De Gramont, A. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N0545 , N9741
Adjuvant mFOLFOX6 +/- Cetuximab in Patients With KRAS Mutant Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147. Goldberg, R. , Sargent, D. , Thibodeau, S. , Mahoney, M. , Shields, A. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - GI - N0147
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. Goldberg, Richard M , Sargent, Daniel J , Morton, Roscoe F ... - - J. Clin. Oncol. - 2004 Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-N9741
Variability of Pelvic MRI Performance in a Prospective Multicenter Rectal Cancer Trial NCCTG N1048 (Alliance) Gollub, Marc J. , Shi, Qian , Nougaret, Stephanie ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N1048
Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147 Gonsalves, Wilson I. , Mahoney, Michelle R. , Sargent, Daniel J. ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0147
Survival Outcomes from CALGB 80803 (Alliance): A Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy for Esophageal Cancer Goodman, Karyn A. , Hall, Nathan , Bekaii-Saab, Tanios , Ou, Fang-Shu ... - ASCO - J. Clin. Oncol. - 2018 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80803
Initial results of CALGB 80803: A randomized phase II trial of pet scan-directed combined modality therapy for esophageal cancer (Alliance) Goodman, Karyn A. , Niedzwiecki, Donna , Hall, Nathan ... - ASCO GI - J Clin Oncol - 2017 Abstract - Primary Endpoint - Preliminary Analysis - GI - CALGB-80803
Local excision of distal rectal cancer: An update of Cancer and Leukemia Group B 8984 Greenberg, J. A. , Shibata, D. , Herndon, J. E. 2nd ... - - Am Soc Colon Rectal Surg - 2008 Abstract - Primary Endpoint - Long-Term-Followup Analysis - GI - C8984
Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. Greenberg, Jacob A , Shibata, David , Herndon, James E ... - - Dis. Colon Rectum - 2008 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - C8984
New lesions vs. growth of existing disease: does it impact prognosis? Grothey, A. , Heun, J. M. , Branda, M. , Goldberg, R. M. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9741
Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): results of the phase II North Central Cancer Treatment Group Study N054C Grothey, A. , Lafky, J. M. , Morlan, B. W. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - GI - N054C
Baseline quality of life (QOL) is a strong and performance status (PS)-independent prognostic factor for overall survival (OS) in patients with metastatic colorectal cancer (mCRC) Grothey, A. , Sargent, D. J. , Szydlo, W. , Zhao, X. , Campbell, M. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer Grothey, A. , Sobrero, A.F. , Shields, A.F. , Yoshino, T. , Paul, J. ... - - N. Engl. J. Med. - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80702
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. Grothey, Axel , Hedrick, Eric E , Mass, Robert D , Sarkar, Somnath ... - - J. Clin. Oncol. - 2008 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9741
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration Grothey, Axel , Sobrero, Alberto F. , Meyerhardt, Jeffrey A. ... - ESMO - Annals of Oncology - 2017 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - CALGB-80702
Associations of Physical Activity with Survival and Progression in Metastatic Colorectal Cancer: Results from CALGB 80405 (Alliance) Guercio, Brendan J. , Venook, Alan P. , Niedzwiecki, Donna ... - ASCO GI - J Clin Oncol - 2017 Abstract - Secondary Endpoint - Preliminary Analysis - GI - CALGB-80405
Associations of Insulin-Like Growth Factor Binding Proteins and Adiponectin with Disease Progression and Mortality in Metastatic Colorectal Cancer: Results from CALGB/SWOG 80405 (Alliance) Guercio, Brendan J. , Venook, Alan P. , Zhang, Sui , Ou, Fang-Shu ... - ASCO - J. Clin. Oncol. - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405
Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance) Guercio, Brendan J. , Zhang, Sui , Niedzwiecki, Donna , Li, Yanping ... - - PLoS ONE - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-89803
Body mass index, weight loss, and progression and mortality in metastatic colorectal cancer (Alliance) Guercio, Brendan J. , Zhang, Sui , Venook, Alan P. , Ou, Fang-Shu ... - AACR - Cancer Res - 2019 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405
Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Guercio, Brendan J , Zhang, Sui , Ou, Fang-Shu , Venook, Alan P ... - - J. Clin. Oncol. - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405
Phase II study of oxaliplatin, 5-FU and RT followed by gemcitabine in patients with unresectable pancreatic cancer. Haddock, M. , Kim, G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N0349
Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. Haddock, Michael G , Swaminathan, Revathi , Foster, Nathan R ... - - J. Clin. Oncol. - 2007 Manuscript - Primary Endpoint - Primary Analysis - GI - N9942
A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance) Halfdanarson, Thorvardur R. , Foster, Nathan R. , Kim, George P. ... - - Oncologist - 2019 Manuscript - Primary Endpoint - Primary Analysis - GI - N064B
A comparison of two methodologies to quantify Thymidylate synthase for predicting survival in patients with colorectal cancer treated on CALGB 89803 Hasson, R. M. , Niedzwiecki, D. ... - AACR - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance) Hatch, Ace J. , Ou, Fang-Shu , Zemla, Tyler , Liu , Star, Mark D. ... - ASCO GI - J. Clin. Oncol - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405
Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance). Hatch, Ace Joseph , Pang, Herbert , Starr, Mark D. , Brady, John C. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80203
Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405 Heinemann, Volker , Niedzwiecki, Donna , Pearline, Rachel ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405
Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741 Heun, James M. , Grothey, Axel , Branda, Megan E. ... - - Oncologist - 2011 Manuscript - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
Evaluation of the Optimal Number of Lesions Needed for Tumor Evaluation Using the Response Evaluation Criteria in Solid Tumors: A North Central Cancer Treatment Group Investigation Hillman, Shauna L. , Ming-Wen, An , O'Connell, Michael J. ... - - J Clin Oncol - 2009 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N9741
Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147 Huang, J. , Sargent, D. J. , Mahoney, M. R. , Shields, A. F. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - N0147
Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147 Huang, J. , Sargent, D. J. , Mahoney, M. R. , Thibodeau, S. N. ... - ASCO GI - J Cin Oncol 29, No 4_suppl (February - 2011 Abstract - Primary Endpoint - Primary Analysis - GI - N0147 , NCCTG-N0147
Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147 Huang, Jocelin , Nair, Suresh G. , Mahoney, Michelle R. ... - - Clin Colorectal Cancer - 2014 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - NCCTG-N0147
Phase I evaluation of sorafenib (SOR) & bevacizumab (BEV) in first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group Trial N0745 Hubbard, J. , Alberts, S. , Loui, W. , Mahoney, M. , Roberts, L. ... - - J. Clin. Oncol. - 2011 Abstract - Primary Endpoint - Primary Analysis - GI - N0745
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group trial N0745 (Alliance) Hubbard, Joleen M. , Mahoney, Michelle R. , Loui, William S. ... - - Target Oncol - 2017 Manuscript - Primary Endpoint - Primary Analysis - GI - N0745
Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set Hubbard, Joleen , Thomas, David M. , Yothers, Greg , Green, Erin ... - - J. Clin. Oncol - 2012 Manuscript - Secondary Endpoint - Comprehensive Analysis - GI - ACCENT , CALGB-89803
Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance) Hurwitz, H. , Cushman, S. , Jiang, C. , Shterev, I. , Mahoney, M. R. ... - - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80203
The vitamin D receptor gene is a determinant of survival in advanced pancreatic cancer patients Innocenti, Federico , Owzar, Kouros , Jiang, Chen , Seiser, Eric ... - ECC - - 2015 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80303
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803 Jackson, N. A. , Fuchs, C. S. , Niedzwiecki, D. , Hollis, D. R. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - C89803
Elderly patients with metastatic esophageal/gastric cancer: a pooled analysis of age-based outcomes from 8 consecutive North Central Cancer Treatment Group (NCCTG) therapeutic trials Jatoi, A. , Foster, N. R. , Egner, J. , Burch, P. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - N064C
Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)1 Jatoi, Aminah , Dakhil, Shaker R. , Foster, Nathan R. , Ma, Cynthia ... - - J Thorac Oncol - 2008 Manuscript - Primary Endpoint - Primary Analysis - GI - N044B
Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147 Jatoi, Aminah , Green, Erin M. , Rowland, Jr. Kendrith M. ... - - Oncology - 2009 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0147
Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). Jatoi, Aminah , Martenson, James A , Foster, Nathan R ... - - Am. J. Clin. Oncol. - 2007 Manuscript - Primary Endpoint - Primary Analysis - GI - N0044
Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma. Jatoi, Aminah , Nguyen, Phuong L , Foster, Nathan , Sun, David ... - - J Support Oncol - 2007 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0242
Phase II Study of Preoperative Pemetrexed, Carboplatin, and Radiation Followed by Surgery for Locally Advanced Esophageal Cancer and Gastroesophageal Junction Tumors Jatoi, Aminah , Soori, Gamini , Foster, Nathan R. , Hiatt, Bradley ... - - J Thorac Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - GI - N044E
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib Joensuu, Heikki , Eriksson, Mikael , Hall, Kirsten Sundby ... - - Cancer - 2014 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - ACOSOG-Z9001
Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E Katipamula, Rajini , Jatoi, Aminah , Foster, Nathan R. ... - - Clin Med Oncol - 2008 Manuscript - Secondary Endpoint - Preliminary Analysis - GI - N044E
Standardization and documentation of surgical and pathologic variables in a multi-institutional trial of adjuvant therapy for pancreatic cancer: Results from ACOSOG Z5031 Katz, M. H. , Merchant, N. B. , Brower, S. , Campbell, M. ... - SSO - SSO Annual Meeting - 2010 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - ACOSOG-Z5031
Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 Trial Katz, Matthew H. G. , Merchant, Nipun B. , Brower, Steven ... - - Ann. Surg. Oncol. - 2011 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - ACOSOG-Z05031
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas Katz, Matthew H. G. , Ou, Fang-Shu , Herman, Joseph M. ... - - BMC Cancer - 2017 Manuscript - No-Endpoint Endpoint - Trial-Description-Only Analysis - GI - A021501
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Katz, Matthew H. G. , Shi, Qian , Ahmad, Syed A. , Herman, Joseph M. ... - - JAMA Surg - 2016 Manuscript - Primary Endpoint - Primary Analysis - GI - A021101
Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101. Katz, Matthew H.G. , Shi, Qian , Ahmad, Syed , Herman, Joseph ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary Endpoint - Primary Analysis - GI - A021101
Borderline resectable pancreatic cancer: Need for Standardization and Methods for Optimal Clinical Trial Design Katz, Matthew HG , Marsh, Robert , Herman, Joseph M. , Shi, Qian ... - - Ann. Surg. Oncol. - 2013 Manuscript - No-Endpoint Endpoint - Comprehensive Analysis - GI - A021101
Alliance for clinical trials in oncology trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas Katz, Matthew , Herman, Joseph M. , Ou, Fang-Shu , Marsh, Robert ... - ASCO - J. Clin. Oncol. - 2017 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - GI - A021501
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). Kemeny, Nancy E , Niedzwiecki, Donna , Hollis, Donna R ... - - J. Clin. Oncol. - 2006 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-9481
North Central Cancer Treatment Group phase II study of panitumumab (Pmab), chemotherapy, and external beam radiation (Chemo-RT) in patients with locally advanced (LA) pancreatic cancer Kim, G. P. , Foster, N. R. , Haddock, M. G. , Dakhil, S. R. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - GI - N064A
Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma Kim, G. P. , Foster, N. R. , Salim, M. , Flynn, P. J. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Primary Endpoint - Primary Analysis - GI - N064B
Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU) and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer Kim, G. P. , Haddock, M. G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Primary Endpoint - Long-Term-Followup Analysis - GI - NCCTG-N0349
Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemicitabine (GEM) in patients with unresectable pancreatic cancer Kim, G. P. , Haddock, M. , Foster, N. R. , Bollinger, J. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Long-Term-Followup Analysis - GI - N0349
Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC) Kim, G. P. , Marsoni, S. , Monges, G. , Allegra, C. J. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - N994C
Phase II of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma Kim, G. P. , Oberg, A. L. , Foster, N. R. , Jaslowski, A. ... - ASCO - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - N034A
Time-dependent patterns of treatment effect and failure as an explanation for the predictive role of deficient mismatch repair (dMMR) in colon cancer. Kim, G. , Marsoni, S. , Monges, G. , Allegra, C. , Thibodeau, S. N. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N994C
Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841 Kim, George P. , Sargent, Daniel J. , Mahoney, Michelle R. ... - - J Clin Oncol - 2009 Manuscript - Primary Endpoint - Primary Analysis - GI - N9841
A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB) Kindler, H. L. , Niedzwiecki, D. , Hollis, D. R. , Oraefo, E. A. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80303
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303) Kindler, Hedy Lee , Niedzwiecki, Donna , Hollis, Donna ... - - J Clin Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-80303
Randomized Phase II Study of Everolimus (E) versus Everolimus plus Bevacizumab (E+B) in Patients (Pts) with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET), CALGB 80701 (Alliance) Kulke, Matthew H. , Niedzwiecki, Donna , Foster, Nathan R. ... - NANETS - Pancreas - 2016 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80701
Randomized Phase II Study of Everolimus Alone (E) versus Everolimus plus Bevacizumab (E+B) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors, CALGB 80701 (Alliance) Kulke, Matthew H. , Niedzwiecki, Donna , Foster, Nathan R. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80701
Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer: CALGB 89904 Kulke, Matthew H. , Tempero, Margaret A. , Niedzwiecki, Donna ... - - J Clin Oncol - 2009 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-89904
Utility of circulating biomarkers as outcome predictors in metastatic colorectal cancer and recurrent glioblastoma multiforme patients treated with bevacizumab/sorafenib Lafky, J. M. , Anderson, S. K. , Morlan, B. W. , Nelson, G. D. ... - AACR - Cancer Res. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N054C
Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BEV) and sorafenib Lafky, J. M. , Bot, B. M. , Morlan, B. W. , Anderson, S. K. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N054C
Genetic variant associations with treatment outcome and safety in metastatic colorectal cancer patients treated with sorafenib and bevacizumab (BEV) as salvage therapy Lafky, J. , Bot, B. , Morlan, B. ... - AACR - Proc Am Assoc Can Res - 2011 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N054C
Utilization of receptor targeted technetium Tc 99m Tilmanocept (lymphoseek injection) to identify and evaluate the pathological status of sentinel lymph nodes vs. elective neck dissection in patients with intraoral squamous cell carcinoma: A preliminary performance evaluation against technetium Tc 99m sulfur colloid in the ACOSOG-Z0360 study Lai, S. Y. , Agrawal, A. ... - SSO - Ann. Surg. Oncol. - 2013 Abstract - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z0360
CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon Lenz, H. , Niedzwiecki, D. , Innocenti, F. , Blanke, C. , Mahoney, M. ... - ESMO - Ann. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - GI - C80405
Association of Variants with Bevacizumab-Induced Hypertension Identified by Exome Sequencing CALGB-80405 (Alliance) Li, Megan , Mulkey, Flora , Jiang, Chen , Venook, Alan P. ... - ASCPT - - 2016 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab Liu, Y. , Starr, M. D. , Bulusu, A. , Pang, H. , Wong, N. S. ... - - Cancer Med - 2013 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-80303
Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051). Lockhart, A C , Reed, C E , Decker, P A , Meyers, B F , Ferguson, M K ... - - Ann. Oncol. - 2014 Manuscript - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z4051
Endpoints for validation of tumor markers for recurrence risk: Recurrence-free interval (RFI), disease-free survival (DFS), overall survival (OS), and colon-cancer specific survival (CCSS) in CALGB 9581 Mahmoud, N. N. , Lopatin, M. , Lee, M. , Clark-Langone, K. ... - - Eur. J. Cancer - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - C9581
Quality of life (QOL) for patients treated with FOLFOX+/-cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) Phase III Trial N0147 Mahoney, M. R. , Sloan, J. A. , Hubbard, J. M. , Liu, H. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
Preliminary Analysis of Cancer and Leukemia Group B (CALGB) 80003: A Phase II Trial of Gemcitabine, 5-Fluorouracil (5FU), and Radiation Therapy (RT) in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma Mamon, H. J. , Niedzwiecki, D. , Hollis, D. R. , Tan, B. , Smith, J. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2005 Abstract - Primary Endpoint - Preliminary Analysis - GI - CALGB-80003
A Phase II Trial of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma: Cancer and Leukemia Group B (CALGB) 80003 Mamon, Harvey J. , Niedzwiecki, Donna , Hollis, Donna ... - - Cancer - 2011 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-80003
Are actual tumor measurements or categorical tumor response status better at predicting overall survival in cancer clinical trials? Mandrekar, M. D. , Hillman, S. L. , Campbell, M. E. , Hobbs, B. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N9741
Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database McCleary, Nadine J. , Meyerhardt, Jeffrey A. , Green, Erin ... - - J. Clin. Oncol - 2013 Manuscript - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (Alliance) McCleary, Nadine J , Hubbard, Joleen , Mahoney, Michelle R ... - - J Geriatr Oncol - 2018 Manuscript - Primary Endpoint - Primary Analysis - GI - N0949
Impact of smoking on patients with stage III colon cancer: Results from CALGB 89803 McCleary, Nadine Jackson , Niedzwiecki, Donna , Hollis, Donna ... - - Cancer - 2010 Manuscript - Secondary Endpoint - Primary Analysis - GI - C89803
NCCTG N0543 (Alliance): A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma McWilliams, Robert R. , Foster, Nathan R. , Mahoney, Michelle R. ... - - Cancer - 2017 Manuscript - Primary Endpoint - Primary Analysis - GI - N0543
Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. McWilliams, Robert R , Goetz, Matthew P , Morlan, Bruce W ... - - Clin Colorectal Cancer - 2007 Manuscript - Primary Endpoint - Primary Analysis - GI - N0341
Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence Mccarter, M. D. , Antonescu, C. R. , Ballman, K. V. , Maki, R. G. ... - - J. Am. Coll. Surg. - 2012 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - ACOSOG-Z9000 , ACOSOG-Z9001
Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database Mccleary, N. A. J. , Meyerhardt, J. , Green, E. , Yothers, G. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
NCCTG phase I/II trial (N9943) of gemcitabine and pemetrexed in patients with biliary tract or gallbladder carcinoma: phase II results Mcwilliams, R. R. , Foster, N. R. , Quevedo, F. J. , Marschke, R. F. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - N9943
Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial Mcwilliams, R. R. , Mahoney, M. R. , Marchello, B. T. , Jatoi, A. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - GI - N0543
A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147. Mcwilliams, R. R. , Mahoney, M. R. , Sargent, D. J. , Nelson, G. D. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
Phase II trial of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin for metastatic colorectal cancer Mcwilliams, R. , Goetz, M. , Morlan, B. , Salim, M. , Rowland, K., Jr ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N0341
Combined-modality therapy of poor prognosis anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B (CALGB) Meropol, N. J. , Niedzwiecki, D. , Shank, B. , Colacchio, T. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2005 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-9281
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B (CALGB 9281). Meropol, Neal J , Niedzwiecki, Donna , Shank, Brenda ... - - J. Clin. Oncol. - 2008 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-9281
Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients treated on CALGB 80203 Meyerhardt, J. A. , Jackson, N. A. , Niedzwiecki, D. , Hollis, D. R. ... - ASCO - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80203
The impact of dietary patterns on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803 Meyerhardt, J. A. , Niedzwiecki, D. , Hollis, D. R. , Saltz, L. B. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary Endpoint - Primary Analysis - GI - C89803
Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803 Meyerhardt, Jeffrey A. , Niedzwiecki, Donna , Hollis, Donna ... - - J Clin Oncol - 2008 Manuscript - Secondary Endpoint - Primary Analysis - GI - C89803
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. Meyerhardt, Jeffrey A , Niedzwiecki, Donna , Hollis, Donna ... - - JAMA - 2007 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
Ratio of metastatic to examined lymph nodes is a powerful predictor of overall survival in rectal cancer: An analysis of Intergroup 0114 Meyers, M. O. , Hollis, D. R. , Mayer, R. J. , Benson, A. B. 3rd ... - ASCO - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - C9081
Use of the ratio of metastatic to examined lymph nodes to predict local recurrence in rectal cancer: Analysis of data from intergroup trial 0114. Meyers, M. O. , Hollis, D. R. , Mayer, R. J. , Goldberg, R. M. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2009 Abstract - Secondary Endpoint - Primary Analysis - GI - INT-0114
Ratio of Metastatic to Examined Lymph Nodes is Predictive of Local Recurrence in Rectal Cancer: Analysis of Data From Intergroup Trial 0114 Meyers, M.O. , Hollis, D.R. , Mayer, R.J. , Goldberg, R.M. ... - SSO - Ann. Surg. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - GI - INT-0114
MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer Miyoshi, Jinsei , Toden, Shusuke , Yoshida, Kazuhiro , Toiyama, Yuji ... - - Sci Rep - 2017 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). Morales-Oyarvide, Vicente , Yuan, Chen , Babic, Ana , Zhang, Sui ... - - J. Natl. Cancer Inst. - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-89803
Multivitamin Use Is Not Associated With Cancer Recurrence or Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 Ng, Kimmie , Meyerhardt, Jeffrey A. , Chan, Jennifer A. ... - - J Clin Oncol - 2010 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-8461 , CALGB-9665
Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803 Ng, Kimmie , Ogino, Shuji , Meyerhardt, Jeffrey A. ... - - J Natl Cancer Inst - 2011 Manuscript - Secondary Endpoint - Primary Analysis - GI - C89803
Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB 80405 (Alliance) Ng, Kimmie , Venook, Alan P. , Sato, Kaori , Hollis, Bruce W. ... - ASCO GI - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405
Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance) Ng, Kimmie , Venook, Alan P. , Sato, Kaori , Yuan, Chen ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405
Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581 Niedzwiecki, Donna , Bertagnolli, Monica M. , Warren, Robert S. ... - - J Clin Oncol - 2011 Manuscript - Primary Endpoint - Primary Analysis - GI - C9581
A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803 Niedzwiecki, Donna , Hasson, Rian M. , Lenz, Heinz‐Josef ... - - Oncologist - 2017 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - C89803 , C9581
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303 Nixon, A. B. , Pang, H. , Starr, M. D. , Hollis, D. R. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80303
Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance) Nixon, Andrew B. , Pang, Herbert , Starr, Mark D. ... - - Clin. Cancer Res. - 2013 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-80303
A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603 O'Reilly, E. M. , Gilman-Rosen, L. F. , Niedzwiecki, D. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80603
A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603) O'Reilly, Eileen M. , Niedzwiecki, Donna , Hall, Margaret ... - - Oncologist - 2010 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-80603
LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin CALGB 80402 Ocean, A. J. , Niedzwiecki, D. , Atkins, J. N. , Parker, B. A. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80402
KRAS mutation is not associated with recurrence or survival in 508 stage III colon cancers: Findings from multicenter adjuvant trial CALGB 89803 Ogino, S. , Meyerhardt, J. A. , Irahara, N. , Niedzwiecki, D. ... - AMP - Annual Meeting Association of Molecular Pathology - 2009 Abstract - Secondary Endpoint - Primary Analysis - GI - C89803
Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial Ogino, Shuji , Liao, Xiaoyun , Imamura, Yu , Yamauchi, Mai ... - - J. Natl. Cancer Inst - 2013 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803 Ogino, Shuji , Meyerhardt, Jeffrey A. , Irahara, Natsumi ... - - Clin Cancer Res - 2009 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803 , C150705
Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803 Ogino, Shuji , Shima, Kaori , Meyerhardt, Jeffrey A. ... - - Clin Cancer Res - 2012 Manuscript - Secondary Endpoint - Primary Analysis - GI - C89803 , C150705
Milestone prediction for time-to-event endpoint monitoring in clinical trials Ou, Fang-Shu , Heller, Martin ... - - Pharm Stat - 2019 Manuscript - No-Endpoint Endpoint - Other Analysis - GI - A151730
Oral Cancer Chemotherapy Adherence and Adherence Assessment Tools: A Report from North Central Cancer Group Trial N0747 and a Systematic Review of the Literature Patel, Krishna , Foster, Nathan R. , Farrell, Ann ... - - J Cancer Educ - 2013 Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-N0747
MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial Pavelitz, Thomas , Renfro, Lindsay , Foster, Nathan R. ... - - PLoS ONE - 2014 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
Smoking status and prognosis in patients with stage III colon cancer: A correlative analysis of NCCTG phase III trial N0147 Phipps, A. I. , Shi, Q. , Limburg, P. L. J. , Nelson, G. D. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary Endpoint - Primary Analysis - GI - N0147
Associations Between Cigarette Smoking Status and Colon Cancer Prognosis Among Participants in North Central Cancer Treatment Group Phase III Trial N0147 Phipps, A. I. , Shi, Q. , Newcomb, P. A. , Nelson, G. D. ... - - J. Clin. Oncol. - 2013 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0147
Pre-diagnostic physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance) Phipps, Amanda I. , Shi, Qian , Chan, Emily , Gill, Sharlene ... - ASPO - - 2017 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0147
Alcohol consumption and colon cancer prognosis among participants in North Central Cancer Treatment Group phase III trial N0147 Phipps, Amanda I. , Shi, Qian , Limburg, Paul J. , Nelson, Garth D. ... - - Int. J. Cancer - 2016 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0147
Alcohol consumption and prognosis in patients with stage III colon cancer: a correlative analysis of NCCTG phase III trial N0147 Phipps, Amanda I. , Shi, Qian , Limburg, Paul J. , Nelson, Garth D. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Primary Analysis - GI - N0147
Physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance) Phipps, Amanda I. , Shi, Qian , Zemla, Tyler J. , Dotan, Efrat ... - - Cancer Epidemiol. Biomarkers Prev. - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0147
Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b–based chemoradiation: ACOSOG Trial Z05031 Picozzi, V. J. , Abrams, R. A. , Decker, P. A. , Traverso, W. ... - - Ann Oncol - 2011 Manuscript - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z05031
Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5- FU, and alpha-interferon Picozzi, V. J. , Abrams, R. A. , Traverso, L. W. , O'Reilly, E. M. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z05031
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Posner, Mitchell C , Niedzwiecki, Donna , Venook, Alan P ... - - Ann. Surg. Oncol. - 2008 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-89903
A phase II study of neoadjuvant therapy with cisplatin, docetaxel, panitumumab plus radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051) Reed, C. , Decker, P. , Schefter, T. , Meyers, B. , Ferguson, M. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Preliminary Analysis - GI - ACOSOG-Z4051
EGFR expression is associated with increased cell turnover and poor histologic grade in human colon carcinomas. Rego, R. L. , Smyrk, T. C. , Foster, N. R. , Sargent, D. J. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0442
Activated EGFR as a prognostic marker in human colon cancer Rego, R. L. , Smyrk, T. C. , Foster, N. R. , Sargent, D. J. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0442
Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials. Renfro, Lindsay A ... - - Chin Clin Oncol - 2016 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0441
Does health-related quality of life (HRQL) improve for patients who respond to chemotherapy? Analysis of patients with advanced pancreas cancer (APC) receiving gemcitabine on Cancer and Leukemia Group B (CALGB) study 80303 Romanus, D. , Archer, L. E. , Wang, X. , Goldberg, R. M. , Mulcahy, M. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80303
Questionable value of attribution when interpreting adverse event data: A joint evaluation by North Central Cancer Treatment Group (NCCTG) and American College of Surgeons Oncology Group (ACOSOG). SL, Hillman , DJ, Sargent , BM, Bot , RP, DeMatteo , EA, Perez ... - ASCO - J Clin Oncol - 2007 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - ACOSOG-Z9001
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. Saltz, Leonard B , Niedzwiecki, Donna , Hollis, Donna ... - - J. Clin. Oncol. - 2007 Manuscript - Primary Endpoint - Primary Analysis - GI - C89803
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. Sandler, Robert S , Halabi, Susan , Baron, John A , Budinger, Susan ... - - N. Engl. J. Med. - 2003 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-9270
Risk stratified analysis improves prediction of treatment (Rx) benefit over subgroup analysis: Findings from Intergroup N9741 Sanoff, H. K. , Campbell, M. E. , Pitot, H. C. , Goldberg, R. M. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
N9741: Survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (Iri) combinations for metastatic colorectal cancer (MCRC) Sanoff, H. K. , Sargent, D. J. , Campbell, M. E. , Morton, R. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Long-Term-Followup Analysis - GI - N9741
Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741 Sanoff, Hanna K. , Sargent, Daniel J. , Campbell, Megan E. ... - - J Clin Oncol - 2008 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - N9741
Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial Sanoff, Hanna K. , Sargent, Daniel J. , Green, Erin M. ... - - J Clin Oncol - 2009 Manuscript - Secondary Endpoint - Primary Analysis - GI - N9741
Overall and 12 week tumor response versus actual tumor measurements as predictors of overall survival (OS) in advanced colorectal cancer (ACRC): Findings from NCCTG N9741. Sargent, D. J. , Campbell, M. E. , Grothey, A. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803. Sargent, D. J. , Yothers, G. , Van Cutsem, E. , Cassidy, J. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - Comprehensive
Benefits and adverse events in younger (age<50) vs. older patients receiving adjuvant chemotherapy for colon cancer: Findings From the 33,574 pt ACCENT dataset. Sargent, D. , Yothers, G. , Green, E. , Blanke, C. , O'Connell, M. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - N0441
Two or Three Year Disease Free Survival (DFS) as a Primary Endpoint in Stage III Adjuvant Colon Cancer Trials with fluoropyrimidines with or without Oxaliplatin or Irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07, and C89803 Sargent, D , Shi, Q , Yothers, G , Van Cutsem, E , Cassidy, J ... - - Eur J Cancer - 2011 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - C89803
Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer Sargent, Daniel J. , Köhne, Claus Henning , Sanoff, Hanna Kelly ... - - J Clin Oncol - 2009 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N9741
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer Sargent, Daniel J. , Marsoni, Silvia , Monges, Genevieve ... - - J Clin Oncol - 2010 Manuscript - Secondary Endpoint - Primary Analysis - GI - N994C
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. Sargent, Daniel J , Patiyil, Smitha , Yothers, Greg ... - - J. Clin. Oncol. - 2007 Manuscript - No-Endpoint Endpoint - Other Analysis - GI - ACCENT
Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: Lessons from the 20,800 patient ACCENT dataset Sargent ... - - J. Clin. Oncol. - 2007 Abstract - Secondary Endpoint - Primary Analysis - GI - N0441
A Phase II Study of Neoadjuvant Therapy with Cisplatin, Docetaxel, Panitumumab Plus Radiation Therapy Followed by Surgery in Patients with Locally Advanced Adenocarcinoma of the Distal Esophagus. (Results of ACOSOG Z4051 (Alliance )) Schefter, T. , Decker, P. , Meyers, B. , Ferguson, M. , Oeltjen, A. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2013 Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z4051
Challenges and Solutions in the Design and Execution of the PROSPECT Phase II/III Neoadjuvant Rectal Cancer Trial (NCCTG N1048/Alliance) Schrag, Deborah , Weiser, Martin , Saltz, Leonard , Mamon, Harvey ... - - Clin Trials - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N1048
Association study of the let-7 microrna-binding site polymorphism in 3-untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147 Sha, D. , Lee, A. , Shi, Q. , Steven, A. R. , Sargent, D. J. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0147
Association study of the let-7 miRNA-complementary site variant in the 3’ untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 clinical trial) Sha, Dan , Lee, Adam , Shi, Qian , Alberts, Steven R. ... - - Clin. Cancer Res. - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
Resampling the N9741 Trial to Compare Tumor Dynamic Versus Conventional End Points in Randomized Phase II Trials Sharma, Manish R. , Gray, Elizabeth , Goldberg, Richard M. ... - - J. Clin. Oncol - 2015 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9741
Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database. Shi, Q. , Hubbard, J. M. , Yothers, G. A. , Andre, T. , Saltz, L. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0441
Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database Shi, Qian , Andre, Thierry , Grothey, Axel , Yothers, Greg ... - - J. Clin. Oncol. - 2013 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803 , NCCTG-784852 , NCCTG-874651 , NCCTG-894651 , NCCTG-914653
Prospective pooled analysis of six phase III trials investigating duration of adjuvant oxaliplatin-based therapy (3 versus 6 months) for patients with stage III colon cancer: The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration (Alliance) Shi, Qian , Sobrero, Alberto , Shields, Anthony , Yoshino, Takayuki ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80702
Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: the IDEA collaboration Shields, Anthony F. , Ou, Fang-Shu , Paul, James ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80702
CpG Island Methylator Phenotype is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage 3 Colon Cancer Shiovitz, Stacey , Bertagnolli, Monica M. , Renfro, Lindsay A. ... - - Gastroenterology - 2014 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance) Singh, Preet Paul , Shi, Qian , Foster, Nathan R. , Grothey, Axel ... - - Oncologist - 2016 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0147
Relationship between Metformin use and Recurrence and Survival in Patients (pts) with Resected Stage III Colon Cancer (CC) Receiving Adjuvant Chemotherapy: Results from NCCTG N0147 (Alliance) Singh, Preet Paul , Shi, Qian , Foster, Nathan , Grothey, Axel ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
Randomized Trial of FOLFOX Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability (ATOMIC, Alliance A021502) Sinicrope FA , Ou, F-S , Shi, Q , Nixon, A , Kabir Mody ... - ASCO - J. Clin. Oncol. - 2017 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - GI - A021502
Prognostic impact of KRAS and BRAFV600E mutations stratified by tumor site in resected stage III colon cancer patients treated with adjuvant mFOLFOX6 with or without cetuximab: NCCTG N0147 (Alliance) Sinicrope, F. A. , Mahoney, M. R. , Smyrk, T. C. , Thibodeau, S. N. ... - - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX +/- cetusimab: NCCTG N0147. Sinicrope, F. A. , Mahoney, M. R. , Smyrk, T. C. , Thibodeau, S. N. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0147
Association of reduced intraepithelial CD3+/regulatory T-cell ratio with poor outcome in human colon cancers Sinicrope, F. A. , Rego, R. L. , Foster, N. R. , Sargent, D. J. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0442
Mutations in the proapoptotic BAX gene are associated with defective DNA mismatch repair and altered tumor growth rates in human colon cancers Sinicrope, F. A. , Rego, R. L. , French, A. J. , Foster, N. R. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0442
Prognostic impact of body-mass index upon cancer recurrence and survival in stage III colon cancer patients treated in adjuvant therapy trials Sinicrope, F. , Foster, N. R. , Sargent, D. J. , Alberts, S. ... - - J. Clin. Oncol. - 2009 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N994C
Evaluation of recurrence rate,time-to-recurrence, and hepatic metastases in patients with colon cancers with defective DNA mismatch repair. Sinicrope, F. , Foster, N. R. , Sargent, D. J. , Thibodeau, S. N. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N994C
DNA Mismatch Repair Status and Site of Tumor Recurrence in Stage II and III Colon Cancers Treated in 5-Fluorouracil-Based Adjuvant Therapy Trials. Sinicrope, F. , Foster, N. , Sargent, D. , Gallinger, S. , Benatti, P. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N994C
Body mass index (BMI) as a prognostic and predictive factor in stage II/III colon cancer: An analysis of the ACCENT database Sinicrope, F. , Foster, N. , Yothers, G. , Benson, A. , Haller, D. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
Obesity Is an Independent Prognostic Variable in Colon Cancer Survivors Sinicrope, Frank A. , Foster, Nathan R. , Sargent, Daniel J. ... - - Clin Cancer Res - 2010 Manuscript - Primary Endpoint - Primary Analysis - GI - N994C
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy Sinicrope, Frank A. , Foster, Nathan R. , Thibodeau, Stephen N. ... - - J Natl Cancer Inst - 2011 Manuscript - Secondary Endpoint - Primary Analysis - GI - N994C
Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant Chemotherapy Trials Sinicrope, Frank A. , Foster, Nathan R. , Yoon, Harry H. ... - - J Clin Oncol - 2012 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N994C
Body Mass Index at Diagnosis and Survival Among Colon Cancer Patients Enrolled in Clinical Trials of Adjuvant Chemotherapy Sinicrope, Frank A. , Foster, Nathan R. , Yothers, Greg , Benson, Al ... - - Cancer - 2013 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0441 , NCCTG-78-48-52 , NCCTG-87-46-51 , NCCTG-89-46-51 , NCCTG-91-46-53 , NCCTG-N0441
Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy Sinicrope, Frank A. , Mahoney, Michelle R. , Smyrk, Thomas C. ... - - J. Clin. Oncol - 2013 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-89803 , N0147
Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance) Sinicrope, Frank A. , Mahoney, Michelle R. , Yoon, Harry H. ... - - Clin. Cancer Res. - 2015 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
Prognostic Impact of Bim, Puma, and Noxa Expression in Human Colon Carcinomas Sinicrope, Frank A. , Rego, Rafaela L. , Okumura, Kenji ... - - Clin Cancer Res - 2008 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0442
Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials Sinicrope, Frank A. , Shi, Qian , Allegra, Carmen Joseph ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147 , NCCTG-N0147
Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance) Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne ... - ESMO GI - Annals of Oncology - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated with Patient Outcomes Sinicrope, Frank A. , Shi, Qian , Smyrk, Thomas C. ... - - Gastroenterology - 2015 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0147
Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)]. Sinicrope, Frank A. , Shi, Qian , Thibodeau, Stephen N. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - GI - N0147
Association Of Tumor Infiltrating Lymphocytes (Tils) With Molecular Subtype And Prognosis In Stage III Colon Cancers From A FOLFOX-Based Adjuvant Chemotherapy Trial: NCCTG N0147 (Alliance) Sinicrope, Frank A. , Smyrk, Thomas C. , Foster, Nathan R. ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0147
Mutation-Specific Antibody Detects Mutant BRAFV600E Protein Expression in Human Colon Carcinomas Sinicrope, Frank A. , Smyrk, Thomas C. , Tougeron, David ... - - Cancer - 2013 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0147
Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147. Sinicrope, Frank A. , Yoon, Harry H. , Mahoney, Michelle R. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - GI - N0147
Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients Sinicrope, Frank , Foster, N.R. , Sargent, D.J. , Thibodeau, S.N. ... - - Cancer - 2010 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N994C
Calibration of Quality-Adjusted Life Years (QALYS) For Oncology Clinical Trials (OCT). Sloan, J. A. , Novotny, P. J. , Sargent, D. J. ... - ISOQOL - ISOQOL - 2010 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-N9741
Clinically Significant Effect Sizes for Survival and Response Endpoints Using the 1/2 Standard Deviation Rule. Sloan, J. A. , Novotny, P. J. , Sargent, D. J. , Decker, P. ... - - Qual Life Res - 2010 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N9741
Tumor burden is not related to quality of life in patients with metastatic colorectal cancer Sloan, J. , Grothey, A. , Green, E. , Zhao, X. , Campbell, M. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
Detection of the BRAFV600E protein in human colon carcinomas by a mutation-specific antibody Smyrk, T. C. , Tougeron, D. , Thibodeau, S. N. , Singh, S. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance) Song, Mingyang , Ou, Fang-Shu , Zemla, Tyler J. , Hull, Mark A. ... - - Int. J. Cancer - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
Postdiagnosis marine omega-3 fatty acid intake and survival of stage III colon cancer in North Central Cancer Treatment Group phase III trial N0147 (Alliance) Song, Mingyang , Ou, Fang-Shu , Zemla, Tyler J. , Shi, Qian ... - DDW - Gastroenterology - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0147
Marine omega-3 polyunsaturated fatty acid intake and survival after colorectal cancer diagnosis Song, Mingyang , Zhang, Xuehong , Meyerhardt, Jeffrey A. ... - - Gut - 2017 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
Current Utilization and Surgical Efficacy of Laparoscopic Colectomy in Colon Cancer Sticca, Robert P , Alberts, Steven R , Mahoney, Michelle R ... - - J. Am. Coll. Surg. - 2013 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
Individual Item Analysis of Quality of Life Assessments Related to Laparoscopic-assisted Colectomy in the COST Trial 93-46-53 (INT 0146) Stucky, C. H. , Pockaj, B. A. , Novotny, P. A. , Sloan, J. A. ... - - Ann. Surg. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-1515
Long-Term Follow-Up and Individual Item Analysis of Quality of Life Assessments Related to Laparoscopic-Assisted Colectomy in the COST Trial 93-46-53 (INT 0146) Stucky, Chee-Chee H. , Pockaj, Barbara A. , Novotny, Paul J. ... - - Ann. Surg. Oncol. - 2011 Manuscript - Secondary Endpoint - Long-Term-Followup Analysis - GI - NCCTG-1515
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer Taieb, Julien , Le Malicot, Karine , Shi, Qian ... - - J. Natl. Cancer Inst - 2016 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials Taieb, Julien , Malicot, Karine Le ... - ASCO - J Clin Oncol - 2015 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N0147
Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781 Tepper, Joel , Krasna, Mark J. , Niedzwiecki, Donna , Hollis, Donna ... - - J. Clin. Oncol. - 2008 Manuscript - Primary Endpoint - Primary Analysis - GI - C9781
Postoperative surveillance recommendations for early-stage colon cancer based on results from the clinical outcomes of surgical therapy trial Tsikitis, V. L. , Malireddy, K. , Green, E. A. , Christensen, B. ... - - J. Clin. Oncol. - 2009 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-934651 , CALGB-9396
Postoperative Surveillance Recommendations for Early Stage Colon Cancer Based on Results From the Clinical Outcomes of Surgical Therapy Trial Tsikitis, Vassiliki L. , Malireddy, Kishore , Green, Erin A. ... - - J Clin Oncol - 2009 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-9396
Use of baseline quality of life (QOL) as compared with performance status (PS) as prognostic factors for overall survival (OS) in patients with metastatic colorectal cancer (mCRC) Turja, J. , Grothey, A. , Sargent, D. , Szydlo, D. , Zhao, X. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance) Van Blarigan, Erin L. , Fuchs, Charles S. , Niedzwiecki, Donna ... - - Cancer Epidemiol. Biomarkers Prev. - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-89803
Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis Van Blarigan, Erin L. , Fuchs, Charles S. , Niedzwiecki, Donna ... - - JAMA Oncol - 2018 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
Dietary fat intake after colon cancer diagnosis in relation to cancer recurrence and survival: CALGB 89803 (Alliance) Van Blarigan, Erin L. , Ou, Fang-Shu , Niedzwiecki, Donna ... - - Cancer Epidemiol. Biomarkers Prev. - 2018 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis and disease-free, recurrence-free, and overall survival CALGB 89803 (Alliance) Van Blarigan, Erin L , Fuchs, Charles S. , Niedzwiecki, Donna ... - ASCO GI - J Clin Oncol - 2017 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance) Van Blarigan, Erin L , Fuchs, Charles S. , Niedzwiecki, Donna ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
25-hydroxyvitamin D levels and survival in patients with advanced pancreatic cancer (APC): Findings from CALGB 80303 Van Loon, K. , Owzar, K. , Jiang, C. , Kindler, H. L. , Mulcahy, M. F. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - C80303
Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients Van Loon, K. , Wigler, D. S. , Niedzwiecki, D. , Hollis, D. R. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - C80405 , C89803
Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405 Van Loon, K. , Wigler, D. , Niedzwiecki, D. , Venook, A. P. ... - - Clin Colorectal Cancer - 2013 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803 , CALGB-80405
Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer?: A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab Van Loon, Katherine , Espinoza, Anne M. , Fogelman, David R. ... - - Pancreas - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N034A
25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance) Van Loon, Katherine , Owzar, Kouros , Jiang, Chen , Kindler, Hedy L. ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-151006 , CALGB-80303
Validation of a 12-gene colon cancer recurrence score (RS) in stage II colon cancer (CC) patients (pts) from CALGB 9581 Venook, A. P. , Niedzwiecki, D. , Lopatin, M. , Lee, M. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - C9581
Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results Venook, A. , Niedzwiecki, D. , Hollis, D. , Sutherland, S. ... - ASCO - J. Clin. Oncol. - 2006 Abstract - Primary Endpoint - Preliminary Analysis - GI - CALGB-80203
CALGB/SWOG 80405: Analysis of patients undergoing surgery as part of treatment strategy Venook, A. , Niedzwiecki, D. , Lenz, H. , Mahoney, M. , Innocenti, F. ... - ESMO - Ann. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405
CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (mFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the colon Venook, A. , Niedzwiecki, D. , Lenz, H.J. , Innocenti, F. ... - ESMO GI - Ann. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80405
Impact of primary (1º) tumor location on overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance) Venook, Alan P. , Niedzwiecki, Donna , Innocenti, Federico ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer Venook, Alan P. , Niedzwiecki, Donna , Lenz, Heinz-Josef ... - - JAMA - 2017 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-80405
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Venook, Alan P. , Niedzwiecki, Donna , Lenz, Heinz-Josef ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80405
Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581 Venook, Alan P. , Niedzwiecki, Donna , Lopatin, Margarita , Ye, Xing ... - - J. Clin. Oncol. - 2013 Manuscript - Secondary Endpoint - Primary Analysis - GI - C9581 , C150705
Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance) Venook, Alan P. , Ou, Fang-Shu , Innocenti, Federico ... - ASCO - J. Clin. Oncol. - 2017
